Literature DB >> 25767098

STAT3-driven transcription depends upon the dimethylation of K49 by EZH2.

Maupali Dasgupta1, Josephine Kam Tai Dermawan2, Belinda Willard3, George R Stark2.   

Abstract

Several transcription factors, including p53, NF-κB, and STAT3, are modified by the same enzymes that also modify histones, with important functional consequences. We have identified a previously unrecognized dimethylation of K49 of STAT3 that is crucial for the expression of many IL-6-dependent genes, catalyzed by the histone-modifying enzyme enhancer of zeste homolog 2 (EZH2). Loss of EZH2 is protumorigenic in leukemias, but its overexpression is protumorigenic in solid cancers. Connecting EZH2 to a functionally important methylation of STAT3, which is constitutively activated in many tumors, may help reveal the basis of the opposing roles of EZH2 in liquid and solid tumors and also may identify novel therapeutic opportunities.

Entities:  

Keywords:  gene expression; histone methyltransferase; posttranslational modification

Mesh:

Substances:

Year:  2015        PMID: 25767098      PMCID: PMC4386339          DOI: 10.1073/pnas.1503152112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  A complex Polycomb issue: the two faces of EZH2 in cancer.

Authors:  Hanno Hock
Journal:  Genes Dev       Date:  2012-04-15       Impact factor: 11.361

2.  Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers.

Authors:  Shuet Theng Lee; Zhimei Li; Zhenlong Wu; Meiyee Aau; Peiyong Guan; R K Murthy Karuturi; Yih Cherng Liou; Qiang Yu
Journal:  Mol Cell       Date:  2011-09-02       Impact factor: 17.970

3.  Stat3 dimerization regulated by reversible acetylation of a single lysine residue.

Authors:  Zheng-Long Yuan; Ying-Jie Guan; Devasis Chatterjee; Y Eugene Chin
Journal:  Science       Date:  2005-01-14       Impact factor: 47.728

Review 4.  Interleukin-6 signaling pathway in targeted therapy for cancer.

Authors:  Yuqi Guo; Feng Xu; TianJian Lu; Zhenfeng Duan; Zhan Zhang
Journal:  Cancer Treat Rev       Date:  2012-05-29       Impact factor: 12.111

Review 5.  STAT3 as a central mediator of neoplastic cellular transformation.

Authors:  David A Frank
Journal:  Cancer Lett       Date:  2006-11-28       Impact factor: 8.679

6.  Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation.

Authors:  Rui Wang; Pratima Cherukuri; Jianyuan Luo
Journal:  J Biol Chem       Date:  2005-01-13       Impact factor: 5.157

7.  EZH2 generates a methyl degron that is recognized by the DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex.

Authors:  Ji Min Lee; Jason S Lee; Hyunkyung Kim; Kyeongkyu Kim; Hyejin Park; Ji-Young Kim; Seung Hoon Lee; Ik Soo Kim; Joomyung Kim; Minkyoung Lee; Chin Ha Chung; Sang-Beom Seo; Jong-Bok Yoon; Eunyoung Ko; Dong-Young Noh; Keun Il Kim; Kyeong Kyu Kim; Sung Hee Baek
Journal:  Mol Cell       Date:  2012-10-11       Impact factor: 17.970

8.  STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor.

Authors:  Yuxin Wang; Anette H H van Boxel-Dezaire; HyeonJoo Cheon; Jinbo Yang; George R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-30       Impact factor: 11.205

9.  Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia.

Authors:  Panagiotis Ntziachristos; Aristotelis Tsirigos; Pieter Van Vlierberghe; Jelena Nedjic; Thomas Trimarchi; Maria Sol Flaherty; Dolors Ferres-Marco; Vanina da Ros; Zuojian Tang; Jasmin Siegle; Patrik Asp; Michael Hadler; Isaura Rigo; Kim De Keersmaecker; Jay Patel; Tien Huynh; Filippo Utro; Sandrine Poglio; Jeremy B Samon; Elisabeth Paietta; Janis Racevskis; Jacob M Rowe; Raul Rabadan; Ross L Levine; Stuart Brown; Francoise Pflumio; Maria Dominguez; Adolfo Ferrando; Iannis Aifantis
Journal:  Nat Med       Date:  2012-02-06       Impact factor: 53.440

Review 10.  EZH2: biology, disease, and structure-based drug discovery.

Authors:  Jin-zhi Tan; Yan Yan; Xiao-xi Wang; Yi Jiang; H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2013-12-23       Impact factor: 6.150

View more
  46 in total

1.  Receptor/gene/protein-mediated signaling connects methylprednisolone exposure to metabolic and immune-related pharmacodynamic actions in liver.

Authors:  Vivaswath S Ayyar; Siddharth Sukumaran; Debra C DuBois; Richard R Almon; Jun Qu; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-04-27       Impact factor: 2.745

2.  Negative regulation of type I IFN signaling by phosphorylation of STAT2 on T387.

Authors:  Yuxin Wang; Jing Nan; Belinda Willard; Xin Wang; Jinbo Yang; George R Stark
Journal:  EMBO J       Date:  2016-11-16       Impact factor: 11.598

3.  EZH2 promotes neoplastic transformation through VAV interaction-dependent extranuclear mechanisms.

Authors:  N Venkatesan; J F Wong; K P Tan; H H Chung; Y H Yau; E Cukuroglu; A Allahverdi; L Nordenskiöld; J Göke; S Geifman-Shochat; V C L Lin; M S Madhusudhan; I-H Su
Journal:  Oncogene       Date:  2017-10-02       Impact factor: 9.867

4.  The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis.

Authors:  Anne Müller; Antje Dickmanns; Claudia Resch; Knut Schäkel; Stephan Hailfinger; Matthias Dobbelstein; Klaus Schulze-Osthoff; Daniela Kramer
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

5.  The regulatory proteins DSCR6 and Ezh2 oppositely regulate Stat3 transcriptional activity in mesoderm patterning during Xenopus development.

Authors:  Mafalda Loreti; De-Li Shi; Clémence Carron
Journal:  J Biol Chem       Date:  2020-01-29       Impact factor: 5.157

Review 6.  Mechanisms and consequences of Jak-STAT signaling in the immune system.

Authors:  Alejandro V Villarino; Yuka Kanno; John J O'Shea
Journal:  Nat Immunol       Date:  2017-03-22       Impact factor: 25.606

7.  FAM64A positively regulates STAT3 activity to promote Th17 differentiation and colitis-associated carcinogenesis.

Authors:  Zhi-Sheng Xu; Hong-Xia Zhang; Wei-Wei Li; Yong Ran; Tian-Tian Liu; Mei-Guang Xiong; Qing-Lan Li; Su-Yun Wang; Min Wu; Hong-Bing Shu; Huimin Xia; Yan-Yi Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-06       Impact factor: 11.205

Review 8.  STAT3 signaling in immunity.

Authors:  Emily J Hillmer; Huiyuan Zhang; Haiyan S Li; Stephanie S Watowich
Journal:  Cytokine Growth Factor Rev       Date:  2016-05-09       Impact factor: 7.638

Review 9.  Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.

Authors:  Uddalak Bharadwaj; Moses M Kasembeli; Prema Robinson; David J Tweardy
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

Review 10.  Signal transducer and activator of transcription 3 signaling as a potential target to treat muscle wasting diseases.

Authors:  David Sala; Alessandra Sacco
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2016-05       Impact factor: 4.294

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.